Tove Tuntland

发表

A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery.

Chun Li, Jonathan Chang, Bo Liu, 2013, Drug discovery today.

A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.

Taebo Sim, Yongping Xie, Nathanael S Gray, 2010, Journal of medicinal chemistry.

Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility.

Yingyao Zhou, Peter G Schultz, Jeffrey Harper, 2008, Nature chemical biology.

Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3.

Jun Li, Glen Spraggon, Tove Tuntland, 2006, Bioorganic & medicinal chemistry letters.

N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta.

Peter Tontonoz, Tove Tuntland, Ansgar Brock, 2007, Journal of medicinal chemistry.

Meister Antimalarial Drug Discovery Liver Stages to Drive Next-Generation Plasmodium Imaging of

Peter G. Schultz, Yingyao Zhou, Jetsumon Sattabongkot, 2012 .

Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research

Tove Tuntland, K. Hoffmaster, F. Blasco, 2014, Front. Pharmacol..

Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases.

Tao Jiang, Bo Liu, Glen Spraggon, 2017, ACS medicinal chemistry letters.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.

Bo Liu, Rose Ann Ferre, Tove Tuntland, 2002, Journal of medicinal chemistry.

Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers.

Jun Li, Glen Spraggon, Tove Tuntland, 2006, Bioorganic & medicinal chemistry letters.

Snapshot PK: a rapid rodent in vivo preclinical screening approach.

Bo Liu, Yingyao Zhou, John Isbell, 2008, Drug discovery today.

Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors.

Jun Li, Tove Tuntland, Jennifer L. Harris, 2006, Bioorganic & medicinal chemistry letters.

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

Glen Spraggon, Badry Bursulaya, Todd Groessl, 2016, Nature.